Akero Therapeutics Inc. (AKRO) — Institutional Holders & Catalysts

Fund Holdings

9 fund convergence

Avoro Capital Advisors

Redmile Group

Eventide Asset Management

AI Signal

AKRO: High-Conviction Biotech Convergence Signal

Avoro's 13% position increase to $187.8M reflects growing confidence among 9 specialist biotech funds in Akero's pipeline, particularly ezetimibe analog MK-3655 (partnered with Merck) for NASH—a large market with limited approved therapies. The deep fund alignment across Baker Bros., OrbiMed, and Perceptive (known for rigorous clinical validation) suggests conviction around upcoming Phase 2b data timing and Merck's development acceleration.

Unlock full AI analysis — 7-day free trial

3 quarters

Position Trend

Nov 14, 2025

$628.1M

8 funds

Feb 13, 2026

0 funds

Feb 17, 2026

0 funds

Mar 16, 2026

0 funds

-100% total institutional value over 7 quarters

Position Details

Avoro Capital AdvisorsEXITMar 16, 2026

Shares: 3,955,555Value: $187.8M

Redmile GroupEXITFeb 17, 2026

Shares: 747,818Value: $35.5M

+ 33more — see how much conviction went in

See the Full Story

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

Akero Therapeutics Inc.

Fund Holdings

Position Trend

Catalysts

Position Details

Know which insider moves are real

Insider Signals

Also Held by These Funds

Research Links